AGT and Cholestatic liver disease: The detrimental impact of the classic RAS pathway mediated by the Angiotensin Converting Enzyme(ACE)/ angiotensin II/Angiotensin II Type 1 Receptor (AT1R), alongside the protective effects of the counterregulatory pathway involving ACE2/Angiotensin 1-7 (Ang 1-7)/Mas receptor (MasR) axis, in liver fibrosis resulting from cholestatic liver disease, has been well-documented (17).